News

Bristol-Myers, Sanofi ink $700M settlement with Hawaii to resolve Plavix lawsuit
Bristol-Myers Squibb (BMY) and Sanofi (SNY) resolve Plavix marketing litigation with Hawaii in $700M settlement. Read more ...
Medscape8d
Single Antiplatelet After TAVR Lowers Risk
New findings from real-world experience support the shift in practice to single antiplatelet therapy after transcatheter ...
MedPage Today11d
DAPT After TAVR: Harm Bleeds Into Mortality Territory
However, guidelines already recommend that antithrombotics after TAVR consist of lifelong SAPT (aspirin 75-100 mg daily or ...
Healio11d
Single antiplatelet therapy linked to reduced mortality after TAVR vs. dual
In a registry of patients who underwent transcatheter aortic valve replacement, those who had single antiplatelet therapy ...
Medscape23d
Clopidogrel–PPI Interaction, an Ongoing Controversy
Although a diminished pharmacodynamic effect of clopidogrel has been demonstrated in patients treated with proton-pump inhibitors (PPIs), whether its clinical efficacy is reduced remains highly ...
Daily24d
Clopidogrel Outperforms Aspirin in Reducing Cardiovascular Events Post-PCI: SMART-CHOICE 3 Trial
South Korea: The SMART-CHOICE 3 trial demonstrated that in patients who had completed the standard course of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), ...
ahajournals.org27d
Abstract P1039: Inhibition Of Drug Metabolizing Enzyme Cytochrome P450 2C8 By Acyl-Glucuronide Metabolites Of Gemfibrozil And Clopidogrel.
The glucuronide metabolites of the antilipemic drug gemfibrozil and the antiplatelet drug clopidogrel are known as strong inhibitors of CYP2C8 leading to several DDIs. Most of the gemfibrozil dose is ...